Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)-Reference-Cited by-同舟云学术

Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)

Published:2019-04 Issue:4 Volume:30 Page:612-620
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Garcia-Sanz R.,Sureda A.,de la Cruz F.,Canales M.,Gonzalez A.P.,Pinana J.L.,Rodriguez A.,Gutierrez A.,Domingo-Domenech E.,Sanchez-Gonzalez B.,Rodriguez G.,Lopez J.,Moreno M.,Rodriguez-Salazar M.J.,Jimenez-Cabrera S.,Caballero M.D.,Martinez C.

Funder

Spanish GELTAMO Foundation

Takeda

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/4/612/28564927/mdz009.pdf

Reference34 articles.

1. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Eichenauer;Ann Oncol,2014

2. Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma;Moskowitz;Hematology Am Soc Hematol Educ Program,2016